Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 3,125 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $16.08, for a total value of $50,250.00. Following the sale, the insider directly owned 315,978 shares in the company, valued at approximately $5,080,926.24. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Francis Lo also recently made the following trade(s):

• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total value of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total value of $1,773,267.30.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT traded down $0.06 during trading on Tuesday, hitting $16.11. 3,352,268 shares of the stock were exchanged, compared to its average volume of 2,104,911. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -29.83 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 1-year low of $5.97 and a 1-year high of $20.76. The company’s fifty day simple moving average is $16.50 and its 200-day simple moving average is $14.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The firm had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.Adaptive Biotechnologies’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same period last year, the business earned ($0.22) earnings per share. On average, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Morgan Stanley started coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Institutional Trading of Adaptive Biotechnologies

Several large investors have recently made changes to their positions in the business. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $30,000. Smartleaf Asset Management LLC lifted its holdings in Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after buying an additional 3,371 shares during the period. Caxton Associates LLP bought a new position in Adaptive Biotechnologies in the first quarter valued at approximately $93,000. Teza Capital Management LLC acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth $118,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $133,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.